Literature DB >> 26372813

Genetic variations in the TERT and CLPTM1L gene region and gastrointestinal stromal tumors risk.

Rui Zhang1, Jian Zhao1, Jian Xu1, Fang Liu1, Yongqing Xu2, Xianmin Bu2, Chaoliu Dai2, Chun Song1.   

Abstract

Recent studies have suggested polymorphisms in the TERT and CLPTM1L region are associated with carcinogenesis of many distinct cancer types, including gastrointestinal cancers. However, the contribution of polymorphisms in the TERT and CLPTM1L gene region to gastrointestinal stromal tumors (GISTs) risk is still unknown. We tested the six tagSNPs on TERT and CLPTM1L region with GIST risk, using a population-based, two-stage, case-control study in 2,000 subjects. Functional validation was conducted to validate our findings of TERT rs2736098 and explore its influence on relative telomere length (RTL) in GIST cells. It showed that variant rs2736098 was significantly associated with increased risk of GIST (per allele OR = 1.29, 95% CI: 1.14-1.47, P = 7.03 × 10-5). The difference remain significant after Bonferroni correction (P = 7.03 × 10-5 * 6 = 4.2 × 10-4). Real-time PCR showed carriers of genotype CC have the longest RTL, following by carriers of genotype CT, while carriers of genotype TT have the shortest RTL in GIST tissues (P < 0.001). Our data provide evidence to implicate TERT rs2736098 polymorphism as a novel susceptibility factor for GIST risk.

Entities:  

Keywords:  CLPTM1L; GIST; TERT; gastrointestinal stromal tumors; polymorphism

Mesh:

Substances:

Year:  2015        PMID: 26372813      PMCID: PMC4741611          DOI: 10.18632/oncotarget.5153

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


INTRODUCTION

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the human digestive tract, representing 1–3% of gastrointestinal malignancies [1, 2]. The histogenesis, classification, diagnostic criteria, and biological behavior of GISTs have been the subject of much controversy [2]. Simply, they are typically defined as tumors whose behavior is driven by mutations in the Kit gene or PDGFRA gene [3-5]. The mechanism of activation in part of sporadic GISTs is an alteration of the structure of the receptor's extracellular or cytoplasmic domains caused by somatic mutations of the c-kit gene, which leads to dimerization and autophosphorylation of KIT with subsequent activation of signal transduction cascades in the absence of ligand binding [6-8]. Inhibition of KIT activity by a specific tyrosine kinase inhibitor, imatinib, often results in dramatic clinical responses [8, 9]. In contrast to GISTs associated with somatic mutations, little is known about inherited germline genetic risk factors. The rarity of the disease makes it a difficult subject to conduct population-based genetic research and unbiased assessment of non-genetic risk factors in any study population. An evaluation of the genetic determinants of GISTs is much more feasible, as the germline DNA of individuals does not change over time or in response to disease processes. Recently, O'Brien et al [10] only evaluated the associations between some candidate SNPs and several common types of acquired KIT and PDGFRA somatic mutations in a case-only study for the first time. However, no other research groups have published such evaluations, not to mention germline genetic associations with GISTs. The TERT and CLPTM1L gene have been identified to be associated with carcinogenesis of at least 15 distinct cancers [11-14]. TERT promoter mutations were also detected in GIST tissues [15]. Recently, six tagSNPs on TERT and CLPTM1L region (five SNPs in the TERT gene: rs7726159, rs2853677, rs2736098, rs13172201, rs10069690; one SNP in CLPTM1L gene: rs451360) were identified, all of which influenced the risk of multiple cancers, including kinds of gastrointestinal cancers [16]. Given this evidence, our main objective was to identify whether these six tagSNPs potentially related to GIST carcinogenesis. Therefore, we first conducted this large population-based, two-stage, case-control study of GIST risk.

RESULTS

A total of 2,000 subjects were included in the current study; 600 were genotyped in Stage I and 1,400 were genotyped in Stage II (Table 1). People in the two genotyping stages were generally comparable. As expected, GIST cases were found to differ from controls in regard to known cancer risk factors: cases were more likely to have a higher education, body mass index (BMI), waist-to-hip ratio (WHR), and more likely to smokers and drinkers. Most of the GISTs were located in stomach (63.8%) or small Intestine (32.5%).
Table 1

Characteristics of the study population

CharacteristicsStage I (N = 600)Stage II (N = 1,400)
Cases (n = 300)Controls (n = 300)P valueCases (n = 700)Controls (n = 700)P value
Age (years)50.0 ± 4.3950.5 ± 4.190.19350.2 ± 3.150.1 ± 3.10.103
Gender (male)234 (78.0%)219 (73.0%)0.154515(73.6%)514 (73.4%)0.952
Education (less than middle school)53(17.7%)34 (11.3%)0.02887(12.4%)86(12.6%)0.998
Body mass index (kg/m2)24.1 ± 2.023.9 ± 2.220.51324.3 ± 2.424.0 ± 2.30.008
Waist-to-hip ratio0.8223 ± 0.0040.8200 ± 0.004<0.00010.8223 ± 0.0040.8199 ± 0.003<0.0001
Regular physical activity83(27.7%)99 (33.0%)0.155181(25.9%)195 (27.9%)0.399
Ever smokers81(27.0%)64(21.3%)0.105201(28.7%)110(15.7%)<0.0001
Ever drinkers88(29.3%)50(16.7%)<0.0001188(26.9%)153(21.9%)0.029
Tumor Location
 Stomach191(63.6%)448(64.0%)
 Small Intestine96(32.0%)228 (32.6%)
 Rectum5 (1.6%)9 (1.3%)
 Other8 (2.6%)15 (2.1%)

Continuous variables: mean values ± standard deviation, p-value from t-tests;

Categorical variables: numbers and percentages, p-values from x2test

P value in bold means statistically significant.

Continuous variables: mean values ± standard deviation, p-value from t-tests; Categorical variables: numbers and percentages, p-values from x2test P value in bold means statistically significant. A total of six tagSNPs on TERT and CLPTM1L region were included in the current study; of these, five SNPs were located in the TERT gene (rs7726159, rs2853677, rs2736098, rs13172201, rs10069690) and one SNP was located in neighboring CLPTM1L gene (rs451360). None of the six polymorphisms were found to deviate from HWE. We first evaluated the six tagSNPs in Stage I with 300 cases and 300 controls. The estimates of effect on GIST risk in Stage I, adjusted for age and gender are shown in Table 2. Three SNPs (rs7726159, rs10069690, and rs2736098) were found to have associations of significance with GIST risk. Then they were evaluated in Stage II with 700 cases and 700 controls additionally (Table 3). One SNP (rs2736098) was replicated with significance (P = 7.03 × 10). The difference remain significant after Bonferroni correction (P = 7.03 × 10 * 6 = 4.2 × 10−4). Compared with individuals with the CC genotype, the age and sex adjusted OR for developing GIST was 1.49 (95% CI 1.18–1.88) among those with the TT genotype. Under the log-additive model, each additional copy of minor allele A was associated with a 1.29-fold increased risk of GIST (OR = 1.29, 95% CI: 1.14–1.47, P = 7.03 × 10).
Table 2

Association between tagSNPs on TERT and CLPTM1L region and GIST risk (Stage I)

SNPAllelesaMAFbAB OR (95% CI)BB OR (95% CI)B vs A OR (95% CI)P
rs7726159C/A0.331.32 (0.93–1.87)1.67 (1.04–2.68)1.33 (1.05–1.69)0.017
rs2853677A/G0.410.94 (0.66–1.34)1.72 (0.41–1.24)0.89 (0.71–1.13)0.894
rs2736098C/T0.371.49 (1.03–2.14)1.78 (1.17–2.72)1.44 (1.14–1.81)1.92 × 10−3
rs13172201C/T0.251.18 (0.82–1.69)1.24 (0.75–2.05)1.17 (0.90–1.50)0.241
rs10069690C/T0.161.36 (0.96–1.93)2.82 (0.91–8.74)1.40 (1.04–1.88)0.025
rs451360C/A0.141.13 (0.76–1.69)1.52 (0.69–3.33)1.22 (0.89–1.68)0.222

Major/minor alleles as determined by allele frequency among genotyped controls

Minor allele frequency among genotyped controls

AA: major allele homozygotes (reference group); AB: heterozygotes; BB: minor allele homozygotes; A: major allele; B: minor allele

P value in bold means statistically significant.

Table 3

Association between tagSNPs on TERT and CLPTM1L region and GIST risk (Stage II)

SNPAllelesaStageAB OR (95% CI)BB OR (95% CI)B vs A OR (95% CI)P
rs7726159C/AI1.32 (0.93–1.87)1.67 (1.04–2.68)1.33 (1.05–1.69)0.017
II0.94 (0.75–1.19)0.95 (0.71–1.29)0.96 (0.82–1.13)0.630
rs10069690C/TI1.36 (0.96–1.93)2.82 (0.91–8.74)1.40 (1.04–1.88)0.025
II0.92 (0.74–1.15)0.83 (0.27–2.49)0.93 (0.77–1.13)0.489
rs2736098C/TI1.49 (1.03–2.14)1.78 (1.17–2.72)1.44 (1.14–1.81)1.92 × 10−3
II1.27 (1.03–1.60)1.38 (1.04–1.83)1.23 (1.06–1.44)6.63 × 10−3
Combined1.33 (1.09–1.101.62)1.49 (1.18–1.88)1.29 (1.14–1.47)7.03 × 10−5

Major/minor alleles as determined by allele frequency among genotyped controls

AA: major allele homozygotes (reference group), AB: heterozygotes, BB: minor allele homozygotes;

P value in bold means statistically significant.

Major/minor alleles as determined by allele frequency among genotyped controls Minor allele frequency among genotyped controls AA: major allele homozygotes (reference group); AB: heterozygotes; BB: minor allele homozygotes; A: major allele; B: minor allele P value in bold means statistically significant. Major/minor alleles as determined by allele frequency among genotyped controls AA: major allele homozygotes (reference group), AB: heterozygotes, BB: minor allele homozygotes; P value in bold means statistically significant. The robustness of these findings was evaluated by sensitivity analyses. First, additional adjustments by education, BMI, WHR, physical activity, drinking and smoking were conducted respectively. The results didn't change materially. To validate our findings of TERT rs2736098 and explore its influence on RTL, we used real-time PCR to measure the RTL in a random sample of 150 GIST cases. In GIST tissues, We found a significant difference in RTLs among the genotype CC, CT, and TT, respectively (Figure 1, P < 0.001).
Figure 1

Boxplot for the RTL with different genotype of SNP rs2736098

DISCUSSION

To the best of our knowledge, this is the first report to attempt an evaluation of the association of six tagSNPs on TERT and CLPTM1L region potentially related to GIST carcinogenesis. In this large population-based, two-stage, case-control study, we identified that the variant rs2736098 was significantly associated with increased risk of GIST, especially for GISTs located in stomach. To validate this finding, real-time PCR showed that the RTL in GIST cells were significantly lower than that of their adjacent normal tissues. And in GIST tissues, carriers of genotype CC have the longest RTL, following by carriers of genotype CT, while carriers of genotype TT have the shortest RTL. These provide evidence to implicate rs2736098 polymorphism as a novel susceptibility factor for GIST risk. GISTs are the most common soft tissue sarcoma of the gastrointestinal tract, resulting most commonly from KIT or platelet-derived growth factor receptor alpha (PDGFRalpha)-activating mutations [19-21]. However, they have distinct genetic background and gene expression patterns according to localization, genotype and aggressiveness [22, 23]. Chr5p15.33 harbors a unique cancer susceptibility region that contains at least two plausible candidate genes: TERT and CLTPM1L [24-27]. The TERT gene has been mapped to chromosome 5p15.33 and consisted of 16 exons and 15 introns spanning 35kb of genomic DNA [28]. It encodes the catalytic subunit of the telomerase reverse transcriptase, which, in combination with an RNA template (TERC), adds nucleotide repeats to chromosome ends [29, 30]. The CLTPM1L gene, also known as cisplatin resistance-related protein 9 (CRR9p), encodes a protein that is overexpressed in lung and pancreatic cancer, promotes growth and survival, and is required for KRAS driven lung cancer [31, 32]. It confer resistance to apoptosis caused by genotoxic agents in association with up-regulation of the anti-apoptotic protein, Bcl-xL [33]. Studies indicate that the TERT-CLPTM1L region may harbor multiple elements that have the capacity to influence molecular phenotypes in cancer development [16, 34]. Thus, It is possible to study that the interplay between risk variants, multiple biological mechanisms and attributed genes, influence various cancers, including GISTs. Although few literature investigating the associations somatic mutations of TERT and GIST risk [15, 35, 36], none has evaluated germline genetic associations with GISTs. In current study, we identified rs2736098 contribute to increased risk of GIST and shorter RTL, using a two-stage, case-control study. This finding is consistent with many previous epidemiological studies with different cancer types, including lung cancer, bladder cancer, pancreatic cancer, gastrointestinal cancers, breast cancer, ovarian cancer, and so on [16, 37–39]. All of evidence above implicate TERT rs2736098 polymorphism as a novel susceptibility factor for carcinogenesis. Considering rs2736098 polymorphism being a tagSNP, it is possible the association seen with rs2736098 tagSNP is due to one of those linked polymorphisms. We additionally listed the detailed information for these 11 linked polymorphisms of rs2736098 in Table 4. Among them, 9 are intergenic SNPs, and 2 are intron variants. Although rs2736098 was a synonymous SNP, our results showed that carriers of genotype CC have the longest RTL, following by carriers of genotype CT, while carriers of genotype TT have the shortest RTL in GIST tissues (P < 0.001). This evidence yet indicate the functionality of SNP rs2736098. Further fine mapping and sequencing studies may be helpful for the validation the our conclusions.
Table 4

Detailed information for linked SNPs of rs2736098

SNPGeneAllelesaPositionsRegion/Functionality
rs2736098TERTC/Tchr5:1293836Exon/synonymous
rs2736109TERTA/Gchr5:1296759intergenic
rs2736108TERTG/Achr5: 1297488intergenic
rs2853672TERTC/Achr5: 1293233intron
rs2735940TERTG/Achr5: 1296736intergenic
rs2736103TERTA/Gchr5: 1300401intergenic
rs2735846TERTC/Gchr5: 1299379intergenic
rs13174919TERTC/Gchr5: 1300112intergenic
rs4975612TERTG/Tchr5: 1300310intergenic
rs13174814TERTC/Gchr5: 1300109intergenic
rs2736099TERTC/Tchr5: 1287340intron
rs2736105TERTA/Gchr5: 1299756intergenic

Major/minor alleles as determined by allele frequency among genotyped controls

Major/minor alleles as determined by allele frequency among genotyped controls Strengths of the current study include a large population, a two-stage genotyping design to minimize type I error, and good coverage of the genetic variation in the TERT and CLPTM1L region. This study also had several limitations. First, selection bias might have occurred through the selection of control subjects when the sampling is not random within the subpopulations of cancer and cancer-free subjects, though we have try our best to control it through the whole process of the study; since this study was restricted to a Chinese Han population, it is uncertain whether our findings can be replicated by other ethnic groups. Second, in spite of the relatively large sample size, the power to elucidate gene–environment interactions was limited because of the small magnitude of the overall association. In summary, our findings regarding genetic variation in the TERT and CLPTM1L region and GIST risk add to the growing body of literature suggesting the importance of this genetic region to cancer development. Further research is needed in this area to understand how changes in telomere length over time may influence GIST carcinogenesis in a prospective setting and interaction with a p53 pathway of development.

MATERIALS AND METHODS

Subjects

The methods were carried out in “accordance” with the approved guidelines. Also, all experimental protocols were approved by the institutional review boards of liaoning cancer hospital and shengjing hospital, and written informed consent was obtained from all participants. Cases were histopathologically confirmed GIST patients. Controls without clinic evidence of gastrointestinal diseases or tumors were randomly selected from a pool of healthy volunteers who visited the general health checkup center of the same hospital for routine scheduled physical exams. Controls were individually matched to cases on sex, ethnicity (Han), age (±5 years). After giving written consent, participants provided demographic information using a standard interviewer-administered questionnaire. Stage I includes 300 GIST cases and 300 controls, while stage II includes 700 GIST cases and 700 controls. Totally incluede in this study were 1,000 cases and 1,000 controls. Five ml of peripheral blood was obtained for DNA extraction.

SNP selection and genotyping

Totally, five SNPs in the TERT gene (rs7726159, rs2853677, rs2736098, rs13172201, rs10069690) and one SNP in neighboring CLPTM1L gene (rs451360) were selected in this study (details in Table 5 and supplementary table 1), according to the previous literature [16]. 5′-Nuclease TaqMan® assays were used to genotype the polymorphisms in 96-well plates on an ABI PRISM 7900HT Sequence Detection system (Applied BioSystems, Foster City, CA, USA). The primers and probes for the TaqMan® assays were designed using Primer Express Oligo Design software v2.0 (ABI PRISM) and are available upon request as TaqMan® Pre-Designed SNP Genotyping Assays. Samples from matched case-control pairs were handled identically and genotyped in the same batch in a blinded fashion. All included SNPs had concordance rates of 100% among duplicates within each platform, and laboratory personnel were blinded to the case–control and QC status of all samples.
Table 5

Basic information for each tagSNP

SNPGeneAllelesaPositionsRegion/Functionality
rs7726159TERTC/Achr5:1282069intron
rs2853677TERTA/Gchr5:1286944intron
rs2736098TERTC/Tchr5:1293836Exon/synonymous
rs13172201TERTC/Tchr5:1269156intron
rs10069690TERTC/Tchr5:1279540intron
rs451360CLPTM1LC/Achr5:1319680intron

Major/minor alleles as determined by allele frequency among genotyped controls

Major/minor alleles as determined by allele frequency among genotyped controls

Relative telomere length (RTL) determination

RTL of GIST cells were measured using quantitative real-time polymerase chain reaction (PCR) as described earlier in a random sample of 150 GIST cases [17]. In short, telomeres and a single-copy gene (β2-globin) were amplified including an internal reference control cell line (CCRF-CEM) to which all samples were compared. The ΔΔCt method was used for calculation of RTL values and a standard curve was created in each PCR run to monitor the PCR efficiency.

Statistical Analyses

Hardy–Weinberg equilibrium (HWE) was tested by comparing observed and expected genotype frequencies among controls (x2 test). Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were determined by logistic regression analyses using models that included adjustment for age and gender. Linkage disequilibrium (LD) was assessed by Haploview [18]. Differences of RTLs among different groups were compared by One-Way ANOVA method. All statistical analyses were conducted with SAS version 9.2 (SAS Institute Inc.). All statistical tests were 2-tailed, and P < 0.05 was interpreted as statistically significant unless otherwise indicated.
  39 in total

1.  The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter.

Authors:  Y S Cong; J Wen; S Bacchetti
Journal:  Hum Mol Genet       Date:  1999-01       Impact factor: 6.150

2.  Telomere length and heredity: Indications of paternal inheritance.

Authors:  Katarina Nordfjäll; Asa Larefalk; Petter Lindgren; Dan Holmberg; Göran Roos
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-28       Impact factor: 11.205

Review 3.  Gastrointestinal stromal tumors: what do we know now?

Authors:  Christopher L Corless
Journal:  Mod Pathol       Date:  2014-01       Impact factor: 7.842

4.  Combined DNA methylation and gene expression profiling in gastrointestinal stromal tumors reveals hypomethylation of SPP1 as an independent prognostic factor.

Authors:  Florian Haller; Jitao David Zhang; Evgeny A Moskalev; Alexander Braun; Claudia Otto; Helene Geddert; Yasser Riazalhosseini; Aoife Ward; Aleksandra Balwierz; Inga-Marie Schaefer; Silke Cameron; B Michael Ghadimi; Abbas Agaimy; Jonathan A Fletcher; Jörg Hoheisel; Arndt Hartmann; Martin Werner; Stefan Wiemann; Ozgür Sahin
Journal:  Int J Cancer       Date:  2014-08-01       Impact factor: 7.396

5.  CRR9/CLPTM1L regulates cell survival signaling and is required for Ras transformation and lung tumorigenesis.

Authors:  Michael A James; Haris G Vikis; Everett Tate; Amy L Rymaszewski; Ming You
Journal:  Cancer Res       Date:  2013-12-23       Impact factor: 12.701

6.  Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors.

Authors:  Katherine A Janeway; Bernadette Liegl; Amy Harlow; Claudia Le; Antonio Perez-Atayde; Harry Kozakewich; Christopher L Corless; Michael C Heinrich; Jonathan A Fletcher
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

7.  Molecular characterization of chromosomal band 5p15.33: a recurrent breakpoint region in mantle cell lymphoma involving the TERT-CLPTM1L locus.

Authors:  Georgia Schilling; Eva Maria Murga Penas; Snjezana Janjetovic; Leticia Oliveira-Ferrer; Melanie Braig; Petra Behrmann; Carsten Bokemeyer; Judith Dierlamm
Journal:  Leuk Res       Date:  2012-11-06       Impact factor: 3.156

8.  Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33.

Authors:  Zhaoming Wang; Bin Zhu; Mingfeng Zhang; Hemang Parikh; Jinping Jia; Charles C Chung; Joshua N Sampson; Jason W Hoskins; Amy Hutchinson; Laurie Burdette; Abdisamad Ibrahim; Christopher Hautman; Preethi S Raj; Christian C Abnet; Andrew A Adjei; Anders Ahlbom; Demetrius Albanes; Naomi E Allen; Christine B Ambrosone; Melinda Aldrich; Pilar Amiano; Christopher Amos; Ulrika Andersson; Gerald Andriole; Irene L Andrulis; Cecilia Arici; Alan A Arslan; Melissa A Austin; Dalsu Baris; Donald A Barkauskas; Bryan A Bassig; Laura E Beane Freeman; Christine D Berg; Sonja I Berndt; Pier Alberto Bertazzi; Richard B Biritwum; Amanda Black; William Blot; Heiner Boeing; Paolo Boffetta; Kelly Bolton; Marie-Christine Boutron-Ruault; Paige M Bracci; Paul Brennan; Louise A Brinton; Michelle Brotzman; H Bas Bueno-de-Mesquita; Julie E Buring; Mary Ann Butler; Qiuyin Cai; Geraldine Cancel-Tassin; Federico Canzian; Guangwen Cao; Neil E Caporaso; Alfredo Carrato; Tania Carreon; Angela Carta; Gee-Chen Chang; I-Shou Chang; Jenny Chang-Claude; Xu Che; Chien-Jen Chen; Chih-Yi Chen; Chung-Hsing Chen; Constance Chen; Kuan-Yu Chen; Yuh-Min Chen; Anand P Chokkalingam; Lisa W Chu; Francoise Clavel-Chapelon; Graham A Colditz; Joanne S Colt; David Conti; Michael B Cook; Victoria K Cortessis; E David Crawford; Olivier Cussenot; Faith G Davis; Immaculata De Vivo; Xiang Deng; Ti Ding; Colin P Dinney; Anna Luisa Di Stefano; W Ryan Diver; Eric J Duell; Joanne W Elena; Jin-Hu Fan; Heather Spencer Feigelson; Maria Feychting; Jonine D Figueroa; Adrienne M Flanagan; Joseph F Fraumeni; Neal D Freedman; Brooke L Fridley; Charles S Fuchs; Manuela Gago-Dominguez; Steven Gallinger; Yu-Tang Gao; Susan M Gapstur; Montserrat Garcia-Closas; Reina Garcia-Closas; Julie M Gastier-Foster; J Michael Gaziano; Daniela S Gerhard; Carol A Giffen; Graham G Giles; Elizabeth M Gillanders; Edward L Giovannucci; Michael Goggins; Nalan Gokgoz; Alisa M Goldstein; Carlos Gonzalez; Richard Gorlick; Mark H Greene; Myron Gross; H Barton Grossman; Robert Grubb; Jian Gu; Peng Guan; Christopher A Haiman; Goran Hallmans; Susan E Hankinson; Curtis C Harris; Patricia Hartge; Claudia Hattinger; Richard B Hayes; Qincheng He; Lee Helman; Brian E Henderson; Roger Henriksson; Judith Hoffman-Bolton; Chancellor Hohensee; Elizabeth A Holly; Yun-Chul Hong; Robert N Hoover; H Dean Hosgood; Chin-Fu Hsiao; Ann W Hsing; Chao Agnes Hsiung; Nan Hu; Wei Hu; Zhibin Hu; Ming-Shyan Huang; David J Hunter; Peter D Inskip; Hidemi Ito; Eric J Jacobs; Kevin B Jacobs; Mazda Jenab; Bu-Tian Ji; Christoffer Johansen; Mattias Johansson; Alison Johnson; Rudolf Kaaks; Ashish M Kamat; Aruna Kamineni; Margaret Karagas; Chand Khanna; Kay-Tee Khaw; Christopher Kim; In-Sam Kim; Jin Hee Kim; Yeul Hong Kim; Young-Chul Kim; Young Tae Kim; Chang Hyun Kang; Yoo Jin Jung; Cari M Kitahara; Alison P Klein; Robert Klein; Manolis Kogevinas; Woon-Puay Koh; Takashi Kohno; Laurence N Kolonel; Charles Kooperberg; Christian P Kratz; Vittorio Krogh; Hideo Kunitoh; Robert C Kurtz; Nilgun Kurucu; Qing Lan; Mark Lathrop; Ching C Lau; Fernando Lecanda; Kyoung-Mu Lee; Maxwell P Lee; Loic Le Marchand; Seth P Lerner; Donghui Li; Linda M Liao; Wei-Yen Lim; Dongxin Lin; Jie Lin; Sara Lindstrom; Martha S Linet; Jolanta Lissowska; Jianjun Liu; Börje Ljungberg; Josep Lloreta; Daru Lu; Jing Ma; Nuria Malats; Satu Mannisto; Neyssa Marina; Giuseppe Mastrangelo; Keitaro Matsuo; Katherine A McGlynn; Roberta McKean-Cowdin; Lorna H McNeill; Robert R McWilliams; Beatrice S Melin; Paul S Meltzer; James E Mensah; Xiaoping Miao; Dominique S Michaud; Alison M Mondul; Lee E Moore; Kenneth Muir; Shelley Niwa; Sara H Olson; Nick Orr; Salvatore Panico; Jae Yong Park; Alpa V Patel; Ana Patino-Garcia; Sofia Pavanello; Petra H M Peeters; Beata Peplonska; Ulrike Peters; Gloria M Petersen; Piero Picci; Malcolm C Pike; Stefano Porru; Jennifer Prescott; Xia Pu; Mark P Purdue; You-Lin Qiao; Preetha Rajaraman; Elio Riboli; Harvey A Risch; Rebecca J Rodabough; Nathaniel Rothman; Avima M Ruder; Jeong-Seon Ryu; Marc Sanson; Alan Schned; Fredrick R Schumacher; Ann G Schwartz; Kendra L Schwartz; Molly Schwenn; Katia Scotlandi; Adeline Seow; Consol Serra; Massimo Serra; Howard D Sesso; Gianluca Severi; Hongbing Shen; Min Shen; Sanjay Shete; Kouya Shiraishi; Xiao-Ou Shu; Afshan Siddiq; Luis Sierrasesumaga; Sabina Sierri; Alan Dart Loon Sihoe; Debra T Silverman; Matthias Simon; Melissa C Southey; Logan Spector; Margaret Spitz; Meir Stampfer; Par Stattin; Mariana C Stern; Victoria L Stevens; Rachael Z Stolzenberg-Solomon; Daniel O Stram; Sara S Strom; Wu-Chou Su; Malin Sund; Sook Whan Sung; Anthony Swerdlow; Wen Tan; Hideo Tanaka; Wei Tang; Ze-Zhang Tang; Adonina Tardon; Evelyn Tay; Philip R Taylor; Yao Tettey; David M Thomas; Roberto Tirabosco; Anne Tjonneland; Geoffrey S Tobias; Jorge R Toro; Ruth C Travis; Dimitrios Trichopoulos; Rebecca Troisi; Ann Truelove; Ying-Huang Tsai; Margaret A Tucker; Rosario Tumino; David Van Den Berg; Stephen K Van Den Eeden; Roel Vermeulen; Paolo Vineis; Kala Visvanathan; Ulla Vogel; Chaoyu Wang; Chengfeng Wang; Junwen Wang; Sophia S Wang; Elisabete Weiderpass; Stephanie J Weinstein; Nicolas Wentzensen; William Wheeler; Emily White; John K Wiencke; Alicja Wolk; Brian M Wolpin; Maria Pik Wong; Margaret Wrensch; Chen Wu; Tangchun Wu; Xifeng Wu; Yi-Long Wu; Jay S Wunder; Yong-Bing Xiang; Jun Xu; Hannah P Yang; Pan-Chyr Yang; Yasushi Yatabe; Yuanqing Ye; Edward D Yeboah; Zhihua Yin; Chen Ying; Chong-Jen Yu; Kai Yu; Jian-Min Yuan; Krista A Zanetti; Anne Zeleniuch-Jacquotte; Wei Zheng; Baosen Zhou; Lisa Mirabello; Sharon A Savage; Peter Kraft; Stephen J Chanock; Meredith Yeager; Maria Terese Landi; Jianxin Shi; Nilanjan Chatterjee; Laufey T Amundadottir
Journal:  Hum Mol Genet       Date:  2014-07-15       Impact factor: 6.150

9.  Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus.

Authors:  Michael A James; Weidong Wen; Yian Wang; Lauren A Byers; John V Heymach; Kevin R Coombes; Luc Girard; John Minna; Ming You
Journal:  PLoS One       Date:  2012-06-04       Impact factor: 3.240

10.  Gastrointestinal stromal tumors: a case-only analysis of single nucleotide polymorphisms and somatic mutations.

Authors:  Katie M O'Brien; Irene Orlow; Cristina R Antonescu; Karla Ballman; Linda McCall; Ronald Dematteo; Lawrence S Engel
Journal:  Clin Sarcoma Res       Date:  2013-10-26
View more
  5 in total

1.  Gastrointestinal Stromal Tumors: Deception to the Eyesight.

Authors:  Fady G Haddad; Magda Daoud; Mayurathan Kesavan; Sherif Andrawes
Journal:  Cureus       Date:  2017-07-31

2.  Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma.

Authors:  Winnie S Liang; William Hendricks; Jeffrey Kiefer; Jessica Schmidt; Shobana Sekar; John Carpten; David W Craig; Jonathan Adkins; Lori Cuyugan; Zarko Manojlovic; Rebecca F Halperin; Adrienne Helland; Sara Nasser; Christophe Legendre; Laurence H Hurley; Karthigayini Sivaprakasam; Douglas B Johnson; Holly Crandall; Klaus J Busam; Victoria Zismann; Valerie Deluca; Jeeyun Lee; Aleksandar Sekulic; Charlotte E Ariyan; Jeffrey Sosman; Jeffrey Trent
Journal:  Genome Res       Date:  2017-04       Impact factor: 9.043

3.  Genetic polymorphisms in the TERT gene and susceptibility to non-small cell lung cancer in a Chinese Han population.

Authors:  Chuanyin Li; Xiaona Wang; Yingfu Li; Xinwen Zhang; Mingbo Sun; Shuyuan Liu; Le Sun; Li Shi; Yufeng Yao
Journal:  Cancer Manag Res       Date:  2018-06-11       Impact factor: 3.989

4.  The rs17084733 variant in the KIT 3' UTR disrupts a miR-221/222 binding site in gastrointestinal stromal tumour: a sponge-like mechanism conferring disease susceptibility.

Authors:  Gloria Ravegnini; César Serrano; Vittorio Simeon; Giulia Sammarini; Margherita Nannini; Erica Roversi; Milena Urbini; Fabrizio Ferrè; Riccardo Ricci; Giuseppe Tarantino; Maria A Pantaleo; Patrizia Hrelia; Sabrina Angelini
Journal:  Epigenetics       Date:  2019-04-13       Impact factor: 4.528

5.  TERT rs10069690 polymorphism and cancers risk: A meta-analysis.

Authors:  Guisheng He; Tao Song; Yazhen Zhang; Xiuxiu Chen; Wei Xiong; Huamin Chen; Chuanwei Sun; Chaoyang Zhao; Yunjing Chen; Huangfu Wu
Journal:  Mol Genet Genomic Med       Date:  2019-08-27       Impact factor: 2.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.